Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
10.89
+0.02 (0.18%)
Dec 20, 2024, 4:00 PM EST - Market closed
Evolus Employees
Evolus had 273 employees as of December 31, 2023. The number of employees increased by 58 or 26.98% compared to the previous year.
Employees
273
Change (1Y)
58
Growth (1Y)
26.98%
Revenue / Employee
$909,619
Profits / Employee
-$203,150
Market Cap
689.57M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Bioventus | 970 |
Relay Therapeutics | 323 |
Kura Oncology | 142 |
Keros Therapeutics | 136 |
Immunome | 55 |
Dianthus Therapeutics | 53 |
Savara | 37 |
Oculis Holding AG | 36 |
EOLS News
- 8 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Evolus, Inc. (EOLS) Q3 2024 Earnings Conference Call Transcript - Seeking Alpha
- 6 weeks ago - Evolus Reports Third Quarter 2024 Results - Business Wire
- 7 weeks ago - Evolus to Participate in Stifel 2024 Healthcare Conference - Business Wire
- 7 weeks ago - Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation - Business Wire
- 7 weeks ago - Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers - Business Wire
- 2 months ago - Evolus to Report Third Quarter Financial Results on November 6, 2024 - Business Wire
- 3 months ago - Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 - Business Wire